BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 2019419)

  • 1. FUT-175 as a potent inhibitor of C5/C3 convertase activity for production of C5a and C3a.
    Inagi R; Miyata T; Maeda K; Sugiyama S; Miyama A; Nakashima I
    Immunol Lett; 1991 Jan; 27(1):49-52. PubMed ID: 2019419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methionine modification impairs the C5-cleavage function of cobra venom factor-dependent C3/C5 convertase.
    Fu Q; McPhie P; Gowda DC
    Biochem Mol Biol Int; 1998 Jun; 45(1):133-44. PubMed ID: 9635137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hybrid proteins of Cobra Venom Factor and cobra C3: tools to identify functionally important regions in Cobra Venom Factor.
    Hew BE; Wehrhahn D; Fritzinger DC; Vogel CW
    Toxicon; 2012 Sep; 60(4):632-47. PubMed ID: 22609532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of FUT-175 (Nafamstat Mesilate) on C3a, C4a and C5a generation in vitro and inflammatory reactions in vivo.
    Issekutz AC; Roland DM; Patrick RA
    Int J Immunopharmacol; 1990; 12(1):1-9. PubMed ID: 2303313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of intermolecular bonds between human factor B and Cobra Venom Factor important for C3 convertase stability.
    Hew BE; Pangburn MK; Vogel CW; Fritzinger DC
    Toxicon; 2020 Sep; 184():68-77. PubMed ID: 32526239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New synthetic inhibitor to the alternative complement pathway.
    Ikari N; Sakai Y; Hitomi Y; Fujii S
    Immunology; 1983 Aug; 49(4):685-91. PubMed ID: 6553561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure and function of recombinant cobra venom factor.
    Kock MA; Hew BE; Bammert H; Fritzinger DC; Vogel CW
    J Biol Chem; 2004 Jul; 279(29):30836-43. PubMed ID: 15131128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion.
    Fritzinger DC; Hew BE; Thorne M; Pangburn MK; Janssen BJ; Gros P; Vogel CW
    Dev Comp Immunol; 2009; 33(1):105-16. PubMed ID: 18760301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosmarinic acid: a new inhibitor of complement C3-convertase with anti-inflammatory activity.
    Englberger W; Hadding U; Etschenberg E; Graf E; Leyck S; Winkelmann J; Parnham MJ
    Int J Immunopharmacol; 1988; 10(6):729-37. PubMed ID: 3198307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. I. Generation of the activated complex.
    Miyama A; Kato T; Horai S; Yokoo J; Kashiba S
    Biken J; 1975 Dec; 18(4):193-204. PubMed ID: 1218074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cobra venom factor (CVF)-induced C3 convertase activity in the hemolymph of Galleria mellonella.
    Phipps D; Menger M; Chadwick JS; Aston WP
    Dev Comp Immunol; 1987; 11(1):37-46. PubMed ID: 3647909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of functionally important amino acid sequences in cobra venom factor using human C3/Cobra venom factor hybrid proteins.
    Hew BE; Fritzinger DC; Pangburn MK; Vogel CW
    Toxicon; 2019 Sep; 167():106-116. PubMed ID: 31207349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrastructure of cobra venom factor-dependent C3/C5 convertase and its zymogen, factor B of human complement.
    Smith CA; Vogel CW; Müller-Eberhard HJ
    J Biol Chem; 1982 Sep; 257(17):9879-82. PubMed ID: 6921201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of anaphylatoxins through proteolytic processing of C3 and C5 by house dust mite protease.
    Maruo K; Akaike T; Ono T; Okamoto T; Maeda H
    J Allergy Clin Immunol; 1997 Aug; 100(2):253-60. PubMed ID: 9275149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of C3a and C5a anaphylatoxins on guinea-pig isolated blood vessels.
    Marceau F; Hugli TE
    J Pharmacol Exp Ther; 1984 Sep; 230(3):749-54. PubMed ID: 6332191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant cobra venom factor.
    Vogel CW; Fritzinger DC; Hew BE; Thorne M; Bammert H
    Mol Immunol; 2004 Jun; 41(2-3):191-9. PubMed ID: 15159065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The complement inhibitor FUT-175 suppresses T cell autoreactivity in experimental autoimmune encephalomyelitis.
    Li Q; Nacion K; Bu H; Lin F
    Am J Pathol; 2009 Aug; 175(2):661-7. PubMed ID: 19608865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The crystal structure of cobra venom factor, a cofactor for C3- and C5-convertase CVFBb.
    Krishnan V; Ponnuraj K; Xu Y; Macon K; Volanakis JE; Narayana SV
    Structure; 2009 Apr; 17(4):611-9. PubMed ID: 19368894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional role of the noncatalytic subunit of complement C5 convertase.
    Rawal N; Pangburn MK
    J Immunol; 2000 Feb; 164(3):1379-85. PubMed ID: 10640753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISAs with monoclonal antibodies.
    Klos A; Ihrig V; Messner M; Grabbe J; Bitter-Suermann D
    J Immunol Methods; 1988 Jul; 111(2):241-52. PubMed ID: 3260926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.